BCR/ABL1 p210 and p190 Diagnostic PCR Bone Marrow
Test Mnemonic
BCRBM1
CPT Codes
- 81206 - QTY (1)
- 81207 - QTY (1)
Aliases
- BCRQL
- SQBCRBM
Performing Laboratory
Cleveland Clinic Laboratories
FDA Category
Laboratory Developed Test
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 4 mL | Blood, peripheral | EDTA (Lavender) | Ambient | Ambient | If patient has low white blood cell count, please collect up to an additional 10mL in EDTA (Lavender) and forward all tubes to performing lab |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 2 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | If specimen is to be stored longer than 48 hours, it should be placed at 2-8 C for up to 3 days. If testing is delayed, store as NUCBUF. |
| Refrigerated | Stored up to 3 days. If testing is delayed, .store as NUCBUF. |
| Frozen | UNACCEPTABLE |
Days Performed
5 days per week
Turnaround Time
5 days
Methodology
| Name | Description |
|---|---|
| Polymerase Chain Reaction (PCR), Quant |
Special Info
Clearly indicate specimen type on label. External client shipping instructions: Ship “Priority Overnight;” do not ship on Fridays or the day preceding a holiday.
Clinical Info
The t(9;22)(q32;q22) BCR-ABL translocation is found by definition in cases of chronic myeloid leukemia (CML), and this abnormality is also found in approximately 25% of adult acute lymphoblastic leukemia (ALL). The vast majority of transcripts in both cases are made up of three variants, e1a2, e13a2, and e14a2, resulting from translocations involving ABL intron 1 and BCR introns 1, 13, or 14. In CML, 95% of the BCR-ABL transcripts are either e13a2 or e14a2 (p210 isoform). In ALL, 70% of transcripts in BCR-ABL positive patients are e1a2 (p190 isoform), and 25% are either e13a2 or e14a2.
Clinical Limitation
This assay does not detect minor or micro breakpoints, microdeletions, or mutations. This assay is designed to detect, but not distinguish between the BCR/ABL1 fusion transcripts e1a2, e13a2 (b2a2) and e14a2 (b3a2). Some specimens with very high levels of BCR/ABL1 major transcript (e13a2 and/or e14a2) may be displayed as a low p190 positive.